Genentech to Present First Clinical Data on Novel Anti-TIGIT Cancer Immunotherapy Tiragolumab at ASCO

South San Francisco, CA -- May 13, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase II CITYSCAPE trial, the first randomized study evaluating the efficacy and safety of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials